Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphoid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Biphenotypic, Acute 1 Carcinoma, Squamous Cell 1

Interventions

Gemcitabine 87 Cisplatin 66 Cystectomy 38 pembrolizumab 35 Docetaxel 25 Nivolumab 24 durvalumab 21 Paclitaxel 19 Magnetic Resonance Spectroscopy 18 Radiotherapy 17 Mitomycin 17 Carboplatin 16 atezolizumab 15 Doxorubicin 14 Cystoscopy 14 BCG Vaccine 13 Surveys and Questionnaires 12 Standard of Care 12 avelumab 11 Sunitinib 10 tremelimumab 9 Transurethral Resection of Bladder 9 Ipilimumab 9 Filgrastim 9 Blood Specimen Collection 9 enfortumab vedotin 8 Specimen Handling 8 Neoadjuvant Therapy 8 Methotrexate 8 Methods 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Urinary Bladder Neoplasms × lirilumab × Clear all

NCT03532451 2024-09-19

PrE0807

PrECOG, LLC.

Phase 1 Completed

43 enrolled 15 charts

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡